November 13, 2014

Press release

Mitsubishi Tanabe Pharma Corporation

Application filed for additional indication for ALS for RADICUT® inj. 30mg and RADICUT® BAG for I.V. Infusion 30mg

Osaka, Japan, November 13, 2014---Mitsubishi Tanabe Pharma Corporation (President & Representative Director, CEO: Masayuki Mitsuka) announced today that it has filed an application for a partial change in manufacturing and marketing approval relating to an additional indication and dosage and usage for Amyotrophic Lateral Sclerosis (ALS) for RADICUT® inj. 30mg and RADICUT® BAG for I.V. Infusion 30mg (generic name: edaravone, hereafter RADICUT®).

ALS is a progressive and intractable disease characterized by muscular atrophy and weakness. Mitsubishi Tanabe Pharma conducted clinical trials in Japan involving ALS patients, which confirmed that patients receiving RADICUT® showed less functional loss than patients receiving a placebo. Accordingly, the Company filed an application for an additional indication for ALS.

RADICUT® is a free-radical scavenger that was discovered by Mitsubishi Tanabe Pharma. As a treatment agent for the acute stage of cerebral infarction, RADICUT® inj. 30mg received manufacturing and marketing approval in 2001, and RADICUT® BAG for I.V. Infusion 30mg received manufacturing and marketing approval in 2010. Both of these formulations are now being marketed in Japan.

Mitsubishi Tanabe Pharma believes that this potential new treatment option will help to support patients with ALS.

End

⟨⟨For Details, Contact the Following Section⟩⟩
Corporate Communications Department
Tel +81-6-6205-5211